Pulse Biosciences, Inc. (Nasdaq: PLSE), a company known for its innovative nPulseTM technology that utilizes proprietary Nanosecond Pulsed Field AblationTM (nanosecond PFA or nsPFATM) energy, has announced the successful enrollment of its first patient in the NANOCLAMP AF Study. This study focuses on the treatment of atrial fibrillation (AF).
The initial procedure took place at St. Helena Hospital in St. Helena, California. This milestone follows the recent approval of the nPulseTM Cardiac Surgical System by the FDA under the Investigational Device Exemption (IDE) program.
The NANOCLAMP AF Study aims to evaluate the efficacy and safety of the nPulse technology, which is designed to deliver precise energy to the heart tissue. This advancement represents a potential shift in how atrial fibrillation, a common heart rhythm disorder, can be treated.
Further updates on the study”s progress and its outcomes are anticipated as more patients are enrolled and treated. The implications of this research may significantly impact the management of atrial fibrillation, benefiting many patients in the future.
